Special Issue

Topoisomerases as Targets for Novel Drug Discovery

Message from the Guest Editor

Dear colleagues, A diverse family of efficient biological nanomachines, DNA topoisomerases monitor vital cellular processes such as replication and transcription. Molecules targeting DNA topoisomerases are wellestablished drugs that are widely used in therapy. However, current clinically used drugs targeting DNA topoisomerases face numerous challenges and limitations. Therefore, intensive research is currently underway to expand the understanding of these intriguing enzymes that modulate DNA topology and to develop new molecules that could overcome these challenges and lead to a new generation of drugs targeting topoisomerases.

In this special issue, Pharmaceuticals invites authors to submit research and review articles discussing new insights, perspectives, and challenges related to the study of topoisomerases and their use as drug targets.

Guest Editor

Prof. Dr. Andrej Perdih

Theory Department, National Institute of Chemistry Ljubljana, Ljubljana, Slovenia

Deadline for manuscript submissions

closed (20 June 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/118016

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

